Preparation and Bioavailability Assessment of SMEDDS Containing Valsartan
- 25 February 2010
- journal article
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 11 (1) , 314-321
Abstract
A self-microemulsifying drug delivery system (SMEDDS) has been developed to enhance diffusion rate and oral bioavailability of valsartan. The solubility of valsartan was checked in different oils, surfactants, and cosurfactants and ternary phase diagrams were constructed to evaluate the microemulsion domain. The valsartan SMEDDS was prepared using Capmul MCM (oil), Tween 80 (surfactant), and polyethylene glycol 400 (cosurfactant). The particle size distribution, zeta potential, and polydispersity index were determined and were found to be 12.3 nm, −0.746, and 0.138, respectively. Diffusion rate of valsartan was measured by in vitro dialysis bag method using phosphate buffer pH 6.8 as diffusion media. Developed high-performance liquid chromatography method was used to determine drug content in diffusion media. Oral bioavailability of valsartan SMEDDS was checked by using rabbit model. Results of diffusion rate and oral bioavailability of valsartan SMEDDS were compared with those of pure drug solution and of marketed formulation. Diffusion of valsartan SMEDDS showed maximum drug release when compared to pure drug solution and marketed formulation. The area under curve and time showed significant improvement as the values obtained were 607 ng h/mL and 1 h for SMEDDS in comparison to 445.36 and 1.36 h for market formulation suggesting significant increase (p < 0.01) in oral bioavailability of valsartan SMEDDS.Keywords
This publication has 26 references indexed in Scilit:
- Design, Optimization, Preparation and Evaluation of Dispersion Granules of Valsartan and Formulation into TabletsCurrent Drug Delivery, 2009
- Improvement of Solubility and Stability of Valsartan by Hydroxypropyl-\boldbeta-CyclodextrinJournal of Inclusion Phenomena and Macrocyclic Chemistry, 2005
- Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: A budget impact analysisClinical Therapeutics, 2005
- Susceptibility to Lipase-Mediated Digestion Reduces the Oral Bioavailability of Danazol After Administration as a Medium-Chain Lipid-Based Microemulsion FormulationPharmaceutical Research, 2004
- Lipids, Lipophilic Drugs, and Oral Drug Delivery—Some Emerging ConceptsJournal of Pharmaceutical Sciences, 2000
- Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrineInternational Journal of Pharmaceutics, 1998
- Lipid-Based Delivery Systems for Improving the Bioavailability and Lymphatic Transport of a Poorly Water-Soluble LTB4 InhibitorJournal of Pharmaceutical Sciences, 1998
- Pharmacokinetic Cyclosporine A profiles under long-term neoral treatment in renal transplant recipients: Does fat intake still matter?Transplantation Proceedings, 1997
- Pharmacokinetics of valsartan in patients with liver diseaseClinical Pharmacology & Therapeutics, 1997
- Influence of lipolysis on drug absorption from the gastro-intestinal tractAdvanced Drug Delivery Reviews, 1997